Recent research published on BioRxIv questioned the CRISPR/Cas9 gene-editing platform based on its preliminary research that found preexisting antibodies to Cas9.
Nevertheless, the tried-and-true enzyme replacement therapies (that have been safely used for years) have antibody formation.
This is an abbreviated version of the in-depth Integrated BioSci Report available in advance to our marketplace subscribers.
The ability to see through some majority opinions to find what facts are really there is a trait that can bring rich rewards in the field of common stocks. It is not easy to develop, however, for the composite opinion of those with whom we associate is a powerful influence upon the minds of all of us. – (The Father of Growth Investing) Philip Fisher
On Jan 09, 2018, the share price of CRISPR Therapeutics (NASDAQ:CRSP), a gene-editing and CAR-T-focused firm to service serious conditions like cancers and genetic diseases, traded slightly down by $0.58 (2.22%) at $25.49 after a similar decline the day prior. Since we recommended the company on Nov. 27, 2017 (shortly over a month ago) to subscribers of Integrated BioSci Investing, the stock added another $5.49 (or 30% in capital appreciation).
The stock seemingly bucked the trend (and traded up) in the midst of the Jan. 04, 2018 announcement regarding the 5M additional common shares issued. Nevertheless, the share price recently took a small haircut due to the new research finding published on BioRxIv that questioned the efficacy and safety of the CRISPR/Cas9 due to the preexisting antibodies to the Cas9 homologous proteins (found in two common bacteria species, staphylococcus aureus and streptococcus pyogenes)